biomea fusion Revenue and Competitors

Biomea Fusion, Inc. was formed in 2017 by a small group of biotech executives. We are dedicated to developing innovative medicines for patients. It is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. The more precise a therapeutic agent is, the better the potential outcomes for individual patients' needs. We are a precision oncology company developing novel small molecules that target aggressive forms of cancer. Patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. With our current program, we are targeting specific changes to the DNA of patients, which can be isolated as key drivers for tumor growth. We leverage our in-house drug design and operational expertise to create novel small molecules against genetically defined forms of cancer. Our goal is to move these potentially breakthrough medicines swiftly through the development process and deliver highly impactful medicines for patients in need.